This is not something to panic about, but it can be alarming if you are not prepared for it
Ozempic (semaglutide) is a GLP-1 receptor agonist licensed in the UK for type 2 diabetes management
It is a research-only package containing five lyophilized vials labeled 50mg per vial for qualified laboratory and analytical use
Obesity causes heart attacks, strokes, diabetes, cancer, joint disease, sleep apnea, he said
However, not all tested GLP-1RAs have consistently demonstrated reductions in cardiovascular events, and the impact on specific cardiovascular outcomes varied among the effective drugs
10.1016/j.jneuroim.2015.05.007 40